Skip to Main Content
Contribute Try STAT+ Today

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is rather modest. We plan to tidy up the Pharmalot grounds, promenade with the official mascot, catch up on our reading, and take a nap or three. And what about you? Holiday shopping is in vogue, of course, if you can navigate crowds. Conversely, you could keep to yourself and winterize your castle. Or brave the politics and convince some folks to get vaccinated. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon. …

The U.S. Food and Drug Administration is laying the groundwork for the rapid review of Omicron-targeted vaccines and drugs if they turn out to be needed, The Wall Street Journal tells us. The agency has been meeting with drug makers and setting guidelines for the studies and data needed to swiftly evaluate products targeting the new Omicron Covid-19 variant. The FDA wants to be sure Omicron shots and therapies work safely and can be made correctly before authorizing their use. Under the rules that the FDA is putting into place, drug makers working on new vaccines would be expected to meet standards similar to those required for authorization of boosters.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment